The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for the experimental once-daily oral version of its blockbuster weight-loss drug Wegovy, the Danish drugmaker said on Friday.

The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only getting wider.

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth platforms. The strategy comes as rival Eli Lilly & Co. is working with telehealth firms to distribute lower-cost vials of its own obesity medication,